Literature DB >> 9850734

Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells.

H Hibasami1, Y Achiwa, H Katsuzaki, K Imai, K Yoshioka, K Nakanishi, Y Ishii, M Hasegawa, T Komiya.   

Abstract

The exposure of human lymphoid leukemia Molt 4B cells to honokiol led to both growth inhibition and the induction of apoptosis. Morphological change showing apoptotic bodies was observed in the cells treated with honokiol. The fragmentation by honokiol of DNA to oligonucleosomal-sized fragments that are characteristics of apoptosis was observed to be concentration- and time-dependent. These findings suggest that growth inhibition by honokiol of Molt 4B cells results from the induction of apoptosis in the cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850734     DOI: 10.3892/ijmm.2.6.671

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  20 in total

1.  Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Kozue Sakao; Shivendra V Singh
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

2.  Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Michael Y Bonner; Jack L Arbiser; Neeraj K Saxena; Dipali Sharma
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

3.  Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.

Authors:  Fei Chen; Tao Wang; Yi-Feng Wu; Ying Gu; Xiao-Li Xu; Shu Zheng; Xun Hu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO.

Authors:  Tao Wang; Fei Chen; Zhe Chen; Yi-Feng Wu; Xiao-Li Xu; Shu Zheng; Xun Hu
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

5.  Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.

Authors:  Hong Luo; Qian Zhong; Li-juan Chen; Xiao-rong Qi; A-fu Fu; Han-shuo Yang; Fan Yang; Hong-gang Lin; Yu-quan Wei; Xia Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-19       Impact factor: 4.553

Review 6.  Honokiol: a novel natural agent for cancer prevention and therapy.

Authors:  S Arora; S Singh; G A Piazza; C M Contreras; J Panyam; A P Singh
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

Review 7.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

8.  Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models.

Authors:  Niang Cheng; Tian Xia; Ying Han; Qing Jun He; Rong Zhao; Jun Rong Ma
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

9.  Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.

Authors:  Jia Hu; Li Juan Chen; Li Liu; Xiang Chen; Ping Li Chen; Guang Yang; Wen Li Hou; Ming Hai Tang; Fan Zhang; Xian Huo Wang; Xia Zhao; Yu Quan Wei
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

10.  The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.

Authors:  Pallavi Banerjee; Aninda Basu; Jack L Arbiser; Soumitro Pal
Journal:  Cancer Lett       Date:  2013-06-07       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.